No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
People
Name
Role
LinkedIn
+ Add new row
Further reading
Title
Author
Link
Type
Date
+ Add new row
Documentaries, videos and podcasts
Title
Date
Link
+ Add new row
Companies
Company
CEO
Location
Products/Services
+ Add new row
News
Title
Author
Date
Publisher
Description
National Comprehensive Cancer Network
September 17, 2019
www.prnewswire.com:443
PLYMOUTH MEETING, Pa., Sept. 17, 2019 /PRNewswire/ -- New research in the September 2019 issue of JNCCN--Journal of the National Comprehensive Cancer Network...
Bio Ascend
August 27, 2019
www.prnewswire.com:443
SANTA MONICA, Calif., Aug. 27, 2019 /PRNewswire/ -- Nearly 46 percent of medical school graduates are women, yet women physicians remain underrepresented in...
Reportlinker
Invalid Date
www.prnewswire.com:443
NEW YORK, Feb. 18, 2019 /PRNewswire/ -- This report analyzes the worldwide markets for Nuclear Medicine Imaging Equipment in US$ Thousand by the following...
January 8, 2019
WebWire
AstraZeneca is announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a new phase in its strategic development. Included in the changes will be the arrival at AstraZeneca of the world-renowned oncology scientist, José Baselga, as well as the creation of: , , , , , , • Therapy area-focused Research and Development units that are responsible for discovery through to late-stage development - one for BioPh...
December 7, 2018
WebWire
AstraZeneca and MedImmune, its global biologics research and development arm, announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression follow...
Industry